chrisvoncsefalvay/vaers-outcomes huggingface dataset:
She got the vaccine, and had no problems at first.  Then she left around 7:00 and then the next day her arm started hurting real bad.  Then her back started hurting, lower back/hip area, which is similar to her regular arthritis pain but she had not had any problems until she got the vaccine.  It has migrated from the hip to the back, and is taking home remedies and it's helping.  She feels the pain worse when she tries to stand, but if she's sitting it's not as bad.   She is waiting for her friend to come and take her to the doctor.
her arm was "killing her" and was still uncomfortable this morning; Arm  pain; This non-serious case was reported by a consumer via call center representative and described the occurrence of arm discomfort in a 69-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included chickenpox (had chickenpox as a child) and shingles (had shingles about 4 years ago).   On 06-AUG-2023, the patient received the 1st dose of Shingrix (right arm). In AUG-2023, less than a day after receiving Shingrix, the patient experienced arm discomfort (Verbatim: her arm was "killing her" and was still uncomfortable this morning) and pain in arm (Verbatim: Arm  pain). The outcome of the arm discomfort and pain in arm were not resolved.   It was unknown if the reporter considered the arm discomfort and pain in arm to be related to Shingrix.     It was unknown if the company considered the arm discomfort and pain in arm to be related to Shingrix.   Additional Information: GSK receipt date: 07-AUG-2023 The case was reported by patient's husband. The patient received her 1st dose of Shingrix in her one day before reporting and reported that her arm was killing her and was still uncomfortable this morning (on the morning of reporting). Consent to follow up with HCP was not asked as the patient was not on the phone. This case is linked with US2023106943, reported by same reporter.; Sender's Comments:  US-GSK-US2023106943:Same reporter
positive Covid results with symptoms; positive Covid results with symptoms; This is a spontaneous report from a contactable nurse (patient). A 56-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiration date not reported), via an unspecified route of administration on 20Dec2020 at single dose for COVID-19 immunization. Medical history included hypertension (diagnosed 3-4 years ago), hyperlipemia (diagnosed 3-4 years ago), supraventricular tachycardia since 2017, and asthma; all ongoing. Family history included hypertension. She has no history of adverse reactions or allergies to any vaccines received previously. The patient's concomitant medications were not reported. The patient explains that she got the COVID-19 vaccine on 20Dec2020. Afterward she had some coughing, so she went for a rapid test and found she tested positive after the vaccine. The patient was wondering if this has been reported previously, where someone tested positive after getting the vaccine. She has never tested positive before. She got the results on 28Dec2020 that she was positive. She was now in a hotel quarantining. She was looking trying to find information on this occurring. Since she was in the hotel, she would prefer to use email as communication for follow-up. The patient noticed the cough on 25Dec2020. She works nights so she stayed home on the 26Dec2020. Then on 27Dec2020 she had the test done and on 28Dec2020 the results were given to her and she was positive. Her second dose was due on 10Jan2020 and it was before the 14 days of quarantine will be up. She was checking to see is there anywhere else she can get the second dose. The patient explains that she has been researching and she wanted to get it because she was with elderly family members. She wanted to know how she was tested positive, what test was used as she had the rapid test. There were no treatments for the events. The caller patient was also experiencing a cough, sore throat, and nasal congestion. There was no shortness or anything else going on at this point. The outcome of the events was not recovered.  Information on the lot/batch number has been requested.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of events Drug ineffective and COVID-19 virus test positive cannot be totally excluded.  The case will be reassessed if additional information becomes available.
I had my blood work on March 8th, and my platelet count normally in around 200, was  39. Subsequent blood work on March 11th, my platelet count went up to 54. I went to see my Primary Care Physician; saw his PA. She sent me for CBC test and platelet test.  That test was on March 11th, blood work came back at 69.  I have another blood test scheduled on March  22nd. Will see what it is.  MY CONCERN is that on Friday March 26 I am scheduled for my second vaccine dose. I am not sure I should take it.
Major shivering with fever; extremely sore muscles; no energy. Onset about 12 hours after vaccine; lasting >15 hours (still in effect).
Pt had itching and rash. No SOB or swollen tongue. No breathing distress. Pt took benadryl at 6pm on 11-12-16. She continued benadryl thru the night every 6 hours. Pt also applied cool washrags to reduce itching.
COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Nurse). The reporter is the patient.  A 67-year-old female patient (not pregnant) received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 02Oct2023 at 10:00 as dose 1, single (Batch/Lot number: unknown) at the age of 67 years, in right arm for covid-19 immunisation. The patient's relevant medical history included: "mixed connective tissue disease" (unspecified if ongoing); "hypertension" (unspecified if ongoing); "shellfish" (unspecified if ongoing); "PCN allergy" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Bactrim, reaction(s): "Drug allergy: bactrim"; Clindamycin, reaction(s): "Drug allergy: clindamycin". Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 2; MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 3 (BOOSTER); MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 4 (BOOSTER); MANUFACTURER UNKNOWN), for COVID-19 immunisation. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Oct2023, outcome "unknown" and all described as "COVID-19 Treatment". Therapeutic measures were taken as a result of vaccination failure, covid-19 with paxlovid from 23Oct2023 to 28Oct2023.   The information on the batch/lot number for bnt162b2 omi xbb.1.5 has been requested and will be submitted if and when received.; Sender's Comments: The efficacy of a vaccine varies from one patient to another and can be affected by different factors; however, a contributory role of the suspect vaccine product to the reported events Vaccination failure and COVID-19 cannot be ruled out.,Linked Report(s) : US-PFIZER INC-202300357315 same reporter/patient, different drug/event;
Pt developed systemic rash the same day as receiving vaccine. Pt was diagnosed with erythema multiforme.
Headache; Fatigue; Fever; Joint pain; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of HEADACHE (Headache), FATIGUE (Fatigue), PYREXIA (Fever) and ARTHRALGIA (Joint pain) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     The patient's past medical history included Pneumonia (Twice last year) and Splenectomy in 2011. Concurrent medical conditions included COPD. Concomitant products included TIOTROPIUM BROMIDE (SPIRIVA) for COPD.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Mar-2021, the patient experienced HEADACHE (Headache), FATIGUE (Fatigue), PYREXIA (Fever) and ARTHRALGIA (Joint pain). On 21-Mar-2021, HEADACHE (Headache), FATIGUE (Fatigue), PYREXIA (Fever) and ARTHRALGIA (Joint pain) had resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 19-Mar-2021, Pyrexia: 100.6 (High) Reaches to 101. On 21-Mar-2021, Pyrexia: 98.7 degrees normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medication details was reported.
severe itching w/in 20min of 1st post exposure booster dose;devel blotchy rash all over body 1PM;started w/significant itching of hands & toes then evolved into bumps all over;went to ER but rash was already starting to resolve;
That evening I had body aches and felt feverish. It continued through the next day and then by dinner time that night I was fine. I had a sore arm, too. That lasted two days. On May 10th, three weeks after second dose - cough, congestion, sore throat. Tested negative for COVID. No treatment - just managed with Tylenol but nothing much since I'm pregnant. I had the cold symptoms for about a week and half. Pregnancy history- third pregnancy - other two were full-term. Estimated date of delivery is May 30, 2021
Bels Palsy- unable to close right eye completely nor lift the eyebrow, not able to open my mouth wide enough and fluid drooled on my right lips. Meds prescribed by the dr. Prednisone and cyclovir for 7 days.
shingles; This non-serious case was reported by a consumer via call center representative and described the occurrence of shingles in a 78-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 06-OCT-2023, the patient received the 2nd dose of Shingrix. In OCT-2023, 10 days after receiving Shingrix, the patient experienced shingles (Verbatim: shingles). The outcome of the shingles was not resolved.   It was unknown if the reporter considered the shingles to be related to Shingrix.     It was unknown if the company considered the shingles to be related to Shingrix.   Additional Information: GSK Receipt Date: 19-OCT-2023 The patient reported that he received dose 2 of Shingrix and 10 days later he had shingles. He went to Healthcare professional the next day and was confirmed it was shingles. The reporter did not consent to follow up.
I do not have vaccine details. Patient developed acute knee swelling and pain requiring drainage. She has subsequently developed L wrist inflammation with swelling and warmth. She also had acute neck and lumbar spine pain.  These are acute polyarthritis sxs  that are new for her.
Allergic reaction & redness, swelling and itchness on left upper arm. no pain or fever.  Treatment: Antihistamine ; Motrin Outcome: will follow up
The patient came to the pharmacy today and said her arm became covered with purple  bruises at the injection site 2 days after receiving her vaccine on 5/11/2021. It has been almost 3 weeks and there is still knot on her right arm. The bruising has faded to a pale yellow color. She did not experience any pain at the injection site but the knot has not gone away.
Some dizziness. Very sore arm. Then at 4:30 I got out of bed to use the bathroom. felt I was fainting, managed to lie on floor then experienced retching but didn't actually throw up.
nasty reaction; This case was reported by a consumer via call center representative and described the occurrence of adverse reaction in a elderly patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included drug allergy (Allergic to Maxitrol).   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced adverse reaction. On an unknown date, the outcome of the adverse reaction was unknown.   It was unknown if the reporter considered the adverse reaction to be related to Shingrix.  Additional information was provided as follows: The age at vaccination was not reported. The patient received Shingrix and experienced nasty reaction. The patient was asking if they could take Tylenol for this. The pharmacist advised not to use it because it reduces vaccines effectiveness.
pt was fine after shot but then within a minute or 2 said she"didn't feel too good" then slip down to ground. Her eyes rolled back and it looked like she shook for a second then immediately came to and said "I'm fine". pt said her face felt warm and just felt weird.
Pt reported that they developed a rash after receiving the first dose of Pizer COVID vaccine 4/27.  Pt came for second dose on 5/18 but was turned down at clinical review.
Chills and body ache reduced by day 2 but armpit on the left side showed some signs of swelling and uncomfortable when left arm touched the armpit. Possible sign s of a swollen lymph node on the same side of injection. Felt a bit swollen on Day 2 but the uncomfortness increased by Day 3 (today). Appears that many patients noticed this side effect.
severe stomach flu like symptoms; protracted vomiting; nausea; abdominal cramping; muscle aches; injection site reaction; This is a spontaneous report from a contactable other hcp (patient). This 68-year-old female patient (pregnant no) received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number En6200), via an unspecified route of administration on 20Feb2021 10:30 AM on left arm at single dose for COVID-19 immunization.  Medical history included high blood pressure.  Concomitant medication included rosuvastatin and hydrochlorothiazide/losartan.  The patient experienced injection site reaction and severe stomach flu like symptoms, nausea, protracted vomiting, abdominal cramping and muscle aches on 20Feb2021 19:00. The patient had not received other vaccine in four weeks. There was no treatment received, no COVID prior vaccination and no COVID tested post vaccination, no known allergies. The outcome of the events was recovering.; Sender's Comments: Drug causality for suspect drug BNT162B2  in the onset of the reported events cannot be excluded .    The impact of this report on the benefit/risk profile of the Pfizer drug is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate
Follow up on 08/19/2003: "Secondary transmission of herpes zoster on 08/06/2002." The ER record states pain.
This is a spontaneous report received from a contactable consumer, the patient. A 40-year-old female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: Unknown) via an unspecified route administration in the right arm on 12Mar2021 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The patient previously received levoquin Zithromax (Z-PAK) and echinacea (MANUFACTURER UNKNOWN) for unspecified indication and experienced drug allergy. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) for unknown indication from an unknown date. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was tested positive for COVID-19. The patient underwent lab test and procedures, which included COVID-19 virus test on 22Mar2021 and tested negative. On16Mar2021, the patient experienced facial numbness on the outside of face and lasted 2-3 days, about a week after, the patient experienced numbness inside mouth and 9 days (20Mar2021) after the vaccine loss of taste, it was still present at the time of report. Therapeutic measures were not taken for the reported events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events facial numbness on the outside of face was resolved on an unknown date in Mar2021, while the clinical outcome of numbness inside mouth was unknown and loss of taste was not recovered at the time of report.   Information about lot number cannot be obtained. No further information is expected.
patient felt faint and eyes rolled back. patient given water and symptoms resolved in 20 minutes; patient felt faint and eyes rolled back. patient given water and symptoms resolved in 20 minutes; This is a spontaneous report from a non-contactable pharmacist.   A 38-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), intramuscular, administered in left arm on 13May2021 (Batch/Lot Number: ew0151) (at the age of 38-years-old) as DOSE NUMBER UNKNOWN, SINGLE for COVID-19 immunisation.  The patient's medical history and concomitant medications were not reported. The patient was not pregnant at time of vaccination. The vaccine was administered in a hospital. There were no other vaccines received in four weeks. It was unknown if the patient had COVID-19 prior to vaccination. On 13May2021, the patient felt faint and eyes rolled back. Patient given water and symptoms resolved in 20 minutes. The events did not require treatment. The outcome of the events was recovered on 13May2021. It was unknown if patient was tested for COVID-19 post vaccination.  No follow up attempts are possible; Information about lot/batch number cannot be requested. No further information is expected.
I started off having headaches. The doctor I saw gave me prednisone. She told me to get Claritin because she thought it was sinus related. On 9/4/2021 I have dizziness that didn't allow me to walk down the hall at work. I became sensitive to sound and light at this time. I was positive Nystagmus 9/23/2021. We did the Epley maneuver and then became negative for nystagmus a week later. My blood pressure went up. I did a EKG which was normal. They thought I had vestibular migraines which I haven't had before in my life. I still go to the neurologist monthly and weekly vestibular therapist appointments. I had an MRI and ECO that came back negative. I use a cane to help with balance when I go to work. At home its easier because I have the walls to use for balance. I have fallen and gotten a concussion. 1/22/2022.
Had a little seizure; Fainted; This is a spontaneous report from a contactable physician (pediatrician). A 20-year-old male patient received meningococcal group b rlp2086 (TRUMENBA), intramuscular, administered in deltoid left on 21Jul2021 (lot number: DW3000; expiration date: Jun2023; NDC number of Trumenba: 0005-0100-10; UPC number of Trumenba: 300050100102) at the age of 20-years-old, as dose number unknown, single for immunization. The patient had no relevant medical history. The patient was not taking concomitant medications. On 21Jul2021, the patient fainted and had a little seizure after receiving TRUMENBA. The vaccine was administered in the physician's office. Patient is going to college admission and it's required. The physician woke him up then gave him some water to drink and some cookie to eat. Physician stated that he did not eat lunch. The events lasted in less than 10 seconds. The patient recovered from the events on 21Jul2021. The physician considered causal relationship as very possible because events occurred in less than 5 seconds after the shot, like after 2-3 seconds. The physician wanted to know if there's any component in the Trumenba that can cause seizure.; Sender's Comments: Based on the close temporal relationship, the association between the events "patient fainted and had a little seizure" with TRUMENBA use can not be fully excluded.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
This case was reported by a consumer via call center representative and described the occurrence of headache in a 67-year-old female patient who received SHINGRIX. On 6th May 2018, the patient received the 1st dose of SHINGRIX .5 ml. In May 2018, several hours after receiving SHINGRIX, the patient experienced headache, erythema of extremities, chills, nausea and feeling bad. The patient was treated with TYLENOL. In May 2018, the outcome of the headache, chills and nausea were recovered/resolved. On an unknown date, the outcome of the erythema of extremities was not recovered/not resolved and the outcome of the feeling bad was unknown. The reporter considered the headache, erythema of extremities, chills and nausea to be related to SHINGRIX. It was unknown if the reporter considered the feeling bad to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX in left arm. The patient experienced a bad headache which she described as dreadful with nausea, shivering and chills after SHINGRIX. The patient began feeling badly late in the afternoon (less than a day after vaccination) and got in bed and took TYLENOL. The redness in her arm she described as two inches across and 4 inches high which was unresolved at the time of reporting. The patient also indicated that her pharmacist and certified pharmacy technician (CPhT) claimed that the SHINGRIX only required one shot. The patient had denied permission to contact their physician.
Sever inflammation of heart/ heart congestion; Abdominal area down to legs fluid retention/ weight gain 30 pounds; Horizontal and vertical rash at the injection site.; This spontaneous case was reported by a consumer and describes the occurrence of CARDITIS (Sever inflammation of heart/ heart congestion) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 023M20A and 029L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Mar-2021, the patient experienced FLUID RETENTION (Abdominal area down to legs fluid retention/ weight gain 30 pounds) and VACCINATION SITE RASH (Horizontal and vertical rash at the injection site.). On an unknown date, the patient experienced CARDITIS (Sever inflammation of heart/ heart congestion) (seriousness criterion medically significant). At the time of the report, CARDITIS (Sever inflammation of heart/ heart congestion), FLUID RETENTION (Abdominal area down to legs fluid retention/ weight gain 30 pounds) and VACCINATION SITE RASH (Horizontal and vertical rash at the injection site.) outcome was unknown.            Concomitant medications were not provided. Treatment included fluid pills (details not provided).  On an unknown date, the following tests were performed but results were not provided: Cardio scan, computerized tomogram, and ultrasound.  Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.   This case was linked to MOD-2021-032565 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 22-Jun-2021: Updated event Carditis.  Case upgraded to serious.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
pt devel T102, diarrhea, h/a, chills lt arm became swollen from mid-upper arm about 3/4 of the way around;pt reported pain down lt arm into lt hand;mom reports swelling as one big hive about an inch riased;